百奥泰：BAT1308注射液联合治疗晚期实体瘤临床试验获批准

Core Viewpoint - The company Baiyao Tai (688177) has received approval from the National Medical Products Administration for its clinical trial application of BAT1308 injection combined with BAT4706 injection and BAT8008 injection for the treatment of advanced solid tumors [1] Group 1 - The clinical trial approval is a significant milestone for the company's research and development efforts in oncology [1] - The approved drugs are aimed at treating advanced solid tumors, indicating the company's focus on addressing critical medical needs in cancer treatment [1] - The announcement reflects the company's ongoing commitment to advancing its pipeline of innovative therapies [1]